02:35:14 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-21 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-30 Kvartalsrapport 2024-Q1
2024-05-24 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2024-05-23 Årsstämma 2024
2024-02-29 Extra Bolagsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-11-23 Kvartalsrapport 2023-Q3
2023-11-14 Extra Bolagsstämma 2023
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-29 Kvartalsrapport 2023-Q1
2023-05-26 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2023-05-25 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2023-02-10 Extra Bolagsstämma 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-25 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2022-05-24 Kvartalsrapport 2022-Q1
2022-05-24 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-28 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2021-05-27 Årsstämma 2021
2021-05-27 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-07-02 Extra Bolagsstämma 2020
2020-05-29 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2020-05-28 Kvartalsrapport 2020-Q1
2020-05-28 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-11-22 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-29 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2019-05-28 Årsstämma 2019
2019-05-17 Kvartalsrapport 2019-Q1
2019-04-02 Extra Bolagsstämma 2019
2019-03-01 Bokslutskommuniké 2018
2018-11-23 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-29 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2018-05-28 Årsstämma 2018
2018-05-18 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
2cureX är verksamma inom cancerbehandling. Idag tillhandahåller bolaget olika verktyg som används av läkare vid behandlingar för att mäta effekt och resistens hos cancerläkemedel på patientens egna cancerceller. Målet är att förkorta behandlingsperioden samt hitta rätt individuell behandling. Idag innehas störst verksamhet på den europeiska marknaden. Huvudkontoret ligger i Köpenhamn.
2023-03-23 08:30:00

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today the launch of an updated Specimen Collection Set. The improvements provide, compared to the previous one, an enhanced preservation of living tumoral cells, a smaller footprint for easier shipment and storage, and the implementation of the new IndiTreat® logo and design. This update is a step towards the CE-Marking of the Specimen Collection Set under the new IVD Regulation (IVD-R), a milestone expected to be achieved within Q2 2023.

Continuous improvement of 2cureX products

2cureX launched the previous IndiTreat® Specimen Collection Set back in 2021. This Set is part of the IndiTreat® family of products and contains all the elements for storage and transportation of the patient tissue samples, from the moment they are collected at hospitals to the moment they are received at the 2cureX labs in Copenhagen. The Set also contains the barcodes that are used for the traceability of each individual sample throughout the process, using 2cureX’s IndiBase proprietary software.

In our effort to constantly improve the performance of IndiTreat®, the company has identified a new transport fluid that enhances the protection and preservation of patient samples through the transportation process. This is an essential step to ensure the viability of the tumoroids and the success of the IndiTreat® test. With the new transport fluid, we have extra safety in case of longer than expected transportation periods, such as flight delays.

The present update of the IndiTreat® Specimen Collection Set is a step towards its CE-Marking under the new IVD Regulation (IVD-R), a milestone expected to be achieved within Q2 2023.

The Specimen Collection Set is the first element where the new IndiTreat® logo and image has been applied. In the coming weeks this new design will be incorporated in all IndiTreat® marketing materials and presentations.

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com